Biogen Inc. (BIIB) and Delta Flight Products (DAL) announced that the companies will collaborate to inform future enhancements to the air travel journey for passengers with reduced mobility. In the United States alone, approximately 5.5 million individuals rely on wheelchairs for mobility. The companies will connect with individuals living with rare disease mobility restrictions at community events to listen and learn about their travel experiences and specific needs. Through these interactions, Biogen and DFP aim to better understand the experiences of passengers with reduced mobility, identify gaps and unmet needs in travel accessibility, and inform future innovations and tools aimed at creating a more equitable flying experience.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
- Biogen granted marketing authorization for Qalsody by EC
- Biogen reports Leqembi approved for treatment of Alzheimer’s in South Korea
- Biotech Alert: Searches spiking for these stocks today
- Biogen acquiring HI-Bio in increased immunology focus, says William Blair